Overview

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Status:
Completed

Trial end date:
2020-10-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of INCB024360 administered in combination with MEDI4736 in subjects with selected advanced solid tumors.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Incyte Corporation

Collaborators:

AstraZeneca
MedImmune LLC

Treatments:

Antibodies, Monoclonal
Durvalumab